Finch Therapeutics Group Inc (FNCH) fair value: what the stock is really worth
As of Jun 1, 2026: fair value of Finch Therapeutics Group Inc $3.79, price $7.45, upside -49.1%, quality 39 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
Watch Finch Therapeutics Group Inc for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card.Watch for freePro now: $1 first month
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Jul 24, 2026.
How to read this chart
60‑month range $0.8800 – $639.60 · fair‑value band $2.83 – $5.65 · the $7.45 price screens above the $3.79 fair value. Dashed = 300-day average. As of Jul 24, 2026.
Follow Finch Therapeutics Group in your weekly email
Every Wednesday you see whether Finch Therapeutics Group is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Finch Therapeutics Group, Inc., a clinical-stage microbiome therapeutics company, develops a novel class of orally administered biological drugs in the United States.
Show more
Finch Therapeutics Group, Inc., a clinical-stage microbiome therapeutics company, develops a novel class of orally administered biological drugs in the United States. The company develops FIN-211, a microbiome candidate designed to address the gastrointestinal and behavioral symptoms of autism spectrum disorder; and FIN-524 for the prevention, diagnosis, theragnosis or treatment of diseases in humans, including ulcerative colitis; FIN-525 for the treatment of Crohn's disease; and other microbiome product candidates. The company has collaboration and license agreements with Takeda Pharmaceutical Company Limited; and license agreements with Skysong Innovations LLC, OpenBiome, Arizona State University, and University of Minnesota. Finch Therapeutics Group, Inc. was incorporated in 2014 and is based in Boston, Massachusetts. On March 22, 2026, Finch Therapeutics Group, Inc., along with its affiliates, filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Delaware.
Stock analysis
Finch Therapeutics Group Inc (FNCH) currently trades at $7.45, while our model-based Fair Value estimate is $3.79, 49.1% below the price, so the stock looks overvalued today.
Show more
Valuation
How firm this estimate is: it rests on 1 models at a data quality of 91/100, which puts the evidence level at low.
Scenario range: $2.83 (bear) to $5.65 (bull), the price of $7.45 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 39/100 (below-average quality), in the Healthcare sector.
Weak Growth: Revenue is shrinking: the last year, the last three and the last five years are all negative.
Finch Therapeutics Group Inc reported revenue of $107K in FY2023 versus $10.2M in FY2019, a compound −68.0%/yr. Reported net income was −$13.9M in FY2024.
Key figures
Market cap $14.8M · EPS (TTM) $−8.80 · Return on equity −67.3% · Return on assets (EBIT) −41.6% · Free cash flow −$31.5M · Net debt $17.5M.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 22 out of 100 (low confidence).
What moves the price
The share trades about 49% below its 52-week high and 20% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at 10% fair-value upside, at −49%, FNCH screens richer than that median.
Fair Value models
Bear $2.83Fair Value $3.79Bull $5.65
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.0/100
Revenue is shrinking: the last year, the last three and the last five years are all negative.
Revenue growth 1 year
−87.6%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−76.0%
’19
’20
’21
’22
’23
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−208.2% (2019) → −31,777.6% (2023)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2024 is a loss year, no rate is defined from a loss
Compare Finch Therapeutics Group Inc with another stock
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 625 stocks
Beats the industry median on 2/5 measures
A mixed picture versus its industry peers.
Valuation
Quality Score40 · Below median
Fair Value upside−49.1% · Below median
Profitability
Return on assets−21.9% · Below median
Operating margin (TTM)0.0% · Above median
Valuation Multiplesvs Biotechnology median · lower = cheaper
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "Finch Therapeutics Group Inc Fair Value". https://www.fairvalue-calculator.com/stock/FNCH
Frequently asked questions
Is Finch Therapeutics Group Inc (FNCH) overvalued or undervalued?
As of Jul 24, 2026, our model estimates a fair value of $3.79 versus the last price from Jun 1, 2026 of $7.45, about −49% upside (overvalued).
What is the fair value of FNCH?
Our model-based fair value for Finch Therapeutics Group Inc is $3.79 (as of Jul 24, 2026), built from audited fundamentals. Last price (from Jun 1, 2026): $7.45.
What is the quality score of FNCH?
Finch Therapeutics Group Inc has a Quality Score of 39/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Finch Therapeutics Group Inc (FNCH)?
Our model-based price target is the fair value of $3.79 (as of Jul 24, 2026) from 1 valuation models. Cautious scenario $2.83, optimistic scenario $5.65. It is a calculation from audited fundamentals, not an analyst target.
What is the Finch Therapeutics Group Inc stock forecast for 2026?
Our models put fair value at $3.79, about −49% upside versus the last price from Jun 1, 2026 of $7.45 (overvalued). Cautious scenario $2.83, optimistic scenario $5.65. The calculation is refreshed regularly with new filings.
What is the intrinsic value of Finch Therapeutics Group Inc (FNCH)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Finch Therapeutics Group Inc it is $3.79 per share (as of Jul 24, 2026), against a price of $7.45. It is the blended result of 1 valuation models (cash flow, earnings, asset, dividend).
Is Finch Therapeutics Group Inc stock overvalued or undervalued in 2026?
As of Jul 24, 2026, FNCH trades above its calculated fair value: price $7.45, fair value $3.79, a gap of about −49% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of FNCH?
No. The price is what the market pays today ($7.45); the fair value is what the company's own numbers justify ($3.79). For Finch Therapeutics Group Inc the two are $3.66 per share apart. That gap is exactly why we show both numbers side by side.
How much is Finch Therapeutics Group Inc worth?
The market values Finch Therapeutics Group Inc at about $14.8M (market capitalisation, as of Jul 24, 2026). Per share that is $7.45; our models calculate a fair value of $3.79 per share.
What do the bullish and bearish scenarios say about FNCH?
Our models span a range for Finch Therapeutics Group Inc: cautious scenario $2.83, base $3.79, optimistic $5.65 per share (as of Jul 24, 2026, price $7.45). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Finch Therapeutics Group Inc (FNCH)?
Balance-sheet figures for Finch Therapeutics Group Inc (as of Jul 24, 2026): return on equity −67.3%. They feed the Quality Score of 39/100, which measures business quality independently of the share price.
How far is FNCH from its 52-week high?
Finch Therapeutics Group Inc trades at $7.45, about 49% below its 52-week high of $14.56 and 20% above the low of $6.21 (as of Jun 1, 2026). Distance from the high says nothing about value: that is what the fair value of $3.79 is for.
Which stocks are comparable to Finch Therapeutics Group Inc?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Regeneron Pharmaceuticals, Inc, argenx SE, CSL Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Finch Therapeutics Group Inc stock attractive at the current price?
The data as of Jul 24, 2026: price $7.45, calculated fair value $3.79 (−49%), Quality Score 39/100, from 1 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of FNCH calculated?
We run Finch Therapeutics Group Inc through 1 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of $3.79, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.5 % above its aggregate fair value. Finch Therapeutics Group Inc itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Finch Therapeutics Group Inc (FNCH)?
The latest price we hold is from Jun 1, 2026 and stands at $7.45. Our model-based fair value is $3.79, about −49% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Finch Therapeutics Group Inc right now?
The price sits above even our optimistic bull case ($5.65). The favourable scenario is already priced in. Weak quality (39/100) and above fair value at the same time, the margin of safety is missing on both counts. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. A fairly wide model range ($2.83 to $5.65) leaves room in how you read the outcome.
Key figures of Finch Therapeutics Group Inc
How large is the market capitalisation of Finch Therapeutics Group Inc (FNCH)?
The market capitalisation of Finch Therapeutics Group Inc is $14.8M. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What are the earnings per share of Finch Therapeutics Group Inc (FNCH)?
Earnings per share at Finch Therapeutics Group Inc are $−8.80. Earnings per share over the last twelve months: total profit spread across every single share.
What is the return on equity of Finch Therapeutics Group Inc (FNCH)?
The return on equity (ROE) of Finch Therapeutics Group Inc is −67.3% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Finch Therapeutics Group Inc (FNCH)?
On an EBIT basis the return on assets of Finch Therapeutics Group Inc is −41.6% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
How much free cash flow does Finch Therapeutics Group Inc (FNCH) generate?
The free cash flow of Finch Therapeutics Group Inc is −$31.5M (fiscal year 2023). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does Finch Therapeutics Group Inc (FNCH) carry?
The net debt of Finch Therapeutics Group Inc is $17.5M (fiscal year 2024). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch Finch Therapeutics Group Inc in the live analysis
One click puts Finch Therapeutics Group Inc on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
Thin data
Jul 24, 2026